• Carl Dambkowski, Chief Medical Officer, sold 5,500 shares of Apogee Therapeutics common stock on May 6, 2026 at weighted average prices of USD 83.92 and USD 84.6.
• He exercised stock options for 4,125 shares at USD 22.86 in the same session.
• Beneficial ownership stood at 207,023 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-058129), on May 08, 2026, and is solely responsible for the information contained therein.